Modicus Prime hosted a panel discussion on AI governance in life sciences featuring Modicus Prime CEO Taylor Chartier, Axendia, Inc. Sandra Rodriguez, and Martin Heitmann.

The Problem: FDA observations and warning letters for Inappropriate AI Usage are reshaping how pharmaceutical manufacturers validate and maintain AI systems. Organizations are struggling to scale AI into GxP environments, validate AI systems and suppliers, maintain AI Audit Readiness, meet auditor expectations, and keep up with evolving regulatory expectations. The AI Management System (AIMS) Software: Ensure pharmaceutical companies’ AI applications are audit-ready with the AI Management System software. The software integrates with QMS & data science tooling for AI validation, AI Supplier Assessments, and Context of Use management, enabling scalable AI Audit Readiness across the enterprise. Key Outcomes: • Centralize validation of AI systems and AI Suppliers, including data, model, and control management. • Maintain a validated state across AI application life cycles, including monitoring and change control. • Scale AI audit readiness across the enterprise. • Reduce compliance risk while improving AI ROI. • Accelerate AI adoption in GxP environments. Who We Serve: Modicus Prime actively contributes to pharmaceutical industry standards and best practices through authorship and participation in ISPE, BioPhorum, PDA, and industry conferences. CEO Taylor Chartier is a co-author of the 2025 ISPE GAMP AI Guide. Producing AI audit artifacts from data science, IT, quality, and compliance, the AIMS software ensures every stakeholder at pharmaceutical companies and CDMOs works compliantly with AI in regulated environments.

Founded 2020